A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus

NCT01283139 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

834

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL: Sifalimumab 200 mg
BIOLOGICAL: Sifalimumab 600 mg
BIOLOGICAL: Sifalimumab 1,200 mg
OTHER: Placebo

Sponsor

MedImmune LLC